Cross-Sector entity
UroGen Pharma is most often covered alongside Accu-Fab, which appears in 3 of these 4 stories. That works out to roughly 0.2 stories per week across a 159-day span. The busiest single day carried 3. pharma accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder.
4 verified stories tracked
Last mentioned: Aug 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
UroGen Pharma is most often covered alongside Accu-Fab, which appears in 3 of these 4 stories. That works out to roughly 0.2 stories per week across a 159-day span. The busiest single day carried 3. pharma accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. UroGen Pharma appears in 4 tracked Cross-Sector stories published from March 3, 2026 through August 8, 2026. Each carries 5 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UroGen Pharma. Shared-story counts are live from our verified record — not editorial picks.
Mayville Engineering’s Q2 results reveal a staggering 173% organic growth in data center and critical power revenue, underscoring the property-tech sector's long-term structural tailwind from artificial intelligence. With a pipeline exceeding $125 million, MEC is a bellwether for the construction boom in digital infrastructure.
Biofuel producer Alto Ingredients posted its fourth straight profitable quarter as crush margins expanded to $0.33 per gallon from $0.11 a year ago and 45Z tax credits kicked in. The results demonstrate how federal low-carbon fuel policy is strengthening the ethanol business case.
Urogen Pharma’s bladder cancer therapy ZUSDURI generated $50.4M in Q2 net product revenue, a 73% sequential jump, as the company activated 1,444 accounts and doubled repeat prescribers. The strong commercial launch highlights robust demand in biotech’s niche oncology space.
Source: themarketsdaily.com · dailypolitical.com
UroGen Pharma and Senseonics reported strong Q4 2025 results, driven by the successful commercial launches of Zasturi and Eversense 365. Both companies are navigating critical transitions—UroGen through new reimbursement codes and Senseonics by assuming full commercial control—positioning them for significant revenue scaling in 2026.
